TKPRPGP raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-23. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
=== Class IV: Asp-based DSPs === The haloacid dehalogenase (HAD) superfamily is a further PP group that uses Asp as a nucleophile and was recently shown to have dual-specificity. These PPs can target both Ser and Tyr, but are thought to have greater specificity towards Tyr. A subfamily of HADs, the Eyes Absent Family (Eya), are also transcription factors and can therefore regulate their own phosphorylation and that of transcriptional cofactor/s, and contribute to the control of gene transcription. The combination of these two functions in Eya reveals a greater complexity of transcriptional gene control than previously thought . A further member of this class is the RNA polymerase II C-terminal domain phosphatase. While this family remains poorly understood, it is known to play important roles in development and nuclear morphology.
The study Radiological Evaluation of Breasts Reconstructed with Lipo-modeling (2005) indicates that the therapeutic efficacy of fat-graft breast reconstruction in the treatment of radiation therapy damage to the chest, the incidental reduction of capsular contracture, and the improved coverage of the breast implants. In fat-graft breast augmentation procedures, there is the risk that the adipocyte tissue can become necrotic, undergo metastatic calcification, develop cysts, and agglomerate into palpable lumps. Although the cause of metastatic calcification is unknown, the post-procedure biological changes occurred to the fat-graft tissue resemble the tissue changes usual to breast surgery procedures, such as reduction mammoplasty. The pre-procedure mammograms were negative for the presence of the malignant neoplasms of breast cancer. In the 17-patient cohort, two women developed breast cancer after the breast augmentation: one woman at 12 months and the second woman at 92 months. Further, the study Cell-assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells (2007), in a 40-woman cohort, the inclusion of adipose stem cells in the grafts of adipocyte fat increased the rate of the corrective success of the autologous fat-grafting procedure.
Haemoglobin electrophoresis is a test that can detect different types of haemoglobin. Haemoglobin is extracted from the red cells, then introduced into a porous gel and subjected to an electrical field. This separates normal and abnormal haemoglobin, which can then be identified and quantified. Isoelectric focusing (IEF) is a technique that can be used to diagnose sickle cell disease and other hemoglobinopathies. The technique separates molecules based on their isoelectric point, or the pH at which they have no net electrical charge. IEF uses an electric charge to separate and identify different types of haemoglobin, which become focused into sharp, stationary bands. The technique can distinguish many types of abnormal haemoglobin. High-performance liquid chromatography (HPLC) is reliable, fully automated, and able to distinguish most types of sickle cell disease, including heterozygous. The method separates and quantifies haemoglobin fractions by measuring their flow rate through a column of absorbent material. DNA analysis using polymerase chain reaction (PCR), to amplify small samples of DNA. Variants of PCR used to diagnose sickle cell disease include amplification-refractory mutation system (ARMS) and allele-specific recombinase polymerase amplification. These tests can identify subtypes of sickle cell disease as well as combination hemoglobinopathies.
Vayda (1952), professor emeritus of anthropology and ecology at Rutgers University Melvin Ember (1953), professor of the City University of New York and editor of Cross-Cultural Research Julian Wolpert (1953), professor of urban planning at the Princeton School of Public and International Affairs Demetrios James Caraley (1954), editor of Political Science Quarterly and president of the Academy of Political Science Peter Kenen (1954), provost, Columbia University and expert in Optimum currency area theory Henry Littlefield (1954), educator, author, historian who initiated political interpretations of The Wonderful Wizard of Oz Stephen Orgel (1954), Shakespeare and Renaissance literature scholar David Rosand (1954), art historian, Columbia University Haldon Chase (1955), Denver-based archeologist, early figure of the Beat Generation Warren I. Cohen (1955), historian at University of Maryland, Baltimore County Harry N. Scheiber (1955), professor and director of the Institute for Legal Research at the UC Berkeley School of Law Jerry Fodor (1956), philosopher at Rutgers University Roy Lubove (1956), professor of social welfare at the University of Pittsburgh Seymour J.
Sources: en.wikipedia.org
== External links == IUPAC's "Glossary of Terms Used in Combinatorial Chemistry" ACS Combinatorial Science (formerly Journal of Combinatorial Chemistry) Combinatorial Chemistry Review "Molecular Diversity". metapress.com. Archived from the original on May 15, 2016. Combinatorial Chemistry and High Throughput Screening Combinatorial Chemistry: an Online Journal SmiLib - A free open-source software for combinatorial library enumeration GLARE - A free open-source software for combinatorial library design
== Interactions == Buspirone has been shown in vitro to be metabolized by the enzyme CYP3A4. This finding is consistent with the in vivo interactions observed between buspirone and these inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), among others:
== Production and release == Long Story Short was created by Raphael Bob-Waksberg, the creator of BoJack Horseman, who was also the executive producer of Tuca & Bertie and Undone. Long Story Short was commissioned as a series in August 2024. Bob-Waksberg serves as the showrunner, and the show is executive-produced by Bob-Waksberg, Noel Bright, and Steven A. Cohen. The production companies are The Tornante Company and ShadowMachine. The main voice cast includes Ben Feldman, Abbi Jacobson, Max Greenfield, Lisa Edelstein, Paul Reiser, Angelique Cabral, and Nicole Byer. Each episode's credits contain the disclaimer "This Program Was Made By Humans", denoting generative AI was not used in production. Shortly before the show's release, it was renewed for a second season. Long Story Short premiered on Netflix on August 22, 2025.
Sources: en.wikipedia.org
ADP + phosphate + peptideout The 3 substrates of this enzyme are ATP, H2O, and peptide, whereas its 3 products are ADP, phosphate, and peptide. This enzyme belongs to the family of hydrolases, specifically those acting on acid anhydrides to catalyse transmembrane movement of substances. The systematic name of this enzyme class is ATP phosphohydrolase (peptide-exporting).
The Money Laundering and Financial Crimes Strategy Act of 1998 required banking agencies to develop anti–money laundering training for examiners, required the Department of the Treasury and other agencies to develop a "National Money Laundering Strategy", created the "High Intensity Money Laundering and Related Financial Crime Area" (HIFCA) Task Forces to concentrate law enforcement efforts at the federal, state and local levels in zones where money laundering is prevalent. HIFCA zones may be defined geographically or can be created to address money laundering in an industry sector, a financial institution, or group of financial institutions. The Intelligence Reform & Terrorism Prevention Act of 2004 amended the Bank Secrecy Act to require the Secretary of the Treasury to prescribe regulations requiring certain financial institutions to report cross-border electronic transmittals of funds, if the Secretary determines that reporting is "reasonably necessary" to prevent money laundering and financing of terrorism. In May 2025, the FBI ordered its agents to prioritize investigation of complex money laundering including "Chinese Money Laundering Organizations."
Urobilin, also known as urochrome, is the chemical primarily responsible for the yellow color of urine. It is a linear tetrapyrrole compound that, along with the related colorless compound urobilinogen, are degradation products of the cyclic tetrapyrrole heme.
== Production == The Netflix docuseries Diagnosis was a production created and produced by Netflix and The New York Times together. It draws from the column written by Dr. Lisa Sanders, who seeks to help patients whose conditions have not been diagnosed and resist treatment. For these episodes, Sanders seeks to crowdsource diagnoses and treatments. She published each case in her column, Diagnosis, in The New York Times and invited readers to help solve each medical mystery. The emphasis is on the process of finding answers and patients are treated with respect. Doctors and patients from around the world have responded. Dr. Sanders has been able to provide each patient with a diagnosis of their case, sometimes leading to treatment, and also giving them a sense of belonging and hope. Each patient’s journey through their diagnosis is shown in a 40-minute episode, where viewers can see the progression of a life-changing movement. The result from this project was a seven-episode docuseries. Diagnosis was released on August 16, 2019, on Netflix.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.